As previously reported, Goldman Sachs analyst Nathan Rich upgraded Humana to Buy from Neutral with a price target of $652, up from $575. Humana’s improved competitive positioning in Medicare Advantage has reaccelerated member growth for 2023 and could deliver multiple years of share gains as many peers face Stars headwinds in 2024, Rich tells investors. He also sees an "attractive and still underappreciated" healthcare services opportunity, with primary care earnings having potential to outperform guidance, the analyst added.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HUM:
- Craig-Hallum upgrades eHealth to Buy on ‘clear signs of life’
- Humana to participate in a conference call with Mizuho
- Managed care company returns will be tough to keep replicating, WSJ says
- Humana to shut down Jupiter, FL, facility, cut 150+ jobs, SFBJ reports
- Starboard takes stake in Wix.com, exits Elanco Animal Health
